IDEAS home Printed from https://ideas.repec.org/a/adp/jgjpps/v6y2018i2p33-35.html
   My bibliography  Save this article

Repurposing the Thalidomide to the Treatment of Irinotecan-Induced Intestinal Mucositis: An Old Drug to a New Use

Author

Listed:
  • Rafaela Miranda Pessoa
  • William Gustavo Lima

    (These authors contributed equally.)

  • Kátia Duarte Vital
  • Valbert Nascimento Cardoso
  • Simone Odília Antunes Fernandes

    (Department of Clinical and Toxicological Analyses, University of Minas Gerais, Brazil)

Abstract

Intestinal mucositis (IM) is an inflammation caused by antitumor therapy, it seems as side effect especially in irinotecan-based protocols. This condition has a negative impact on patient’s quality of life and treatment effectiveness, once restricts food intake and may predispose the patient to secondary infections. Currently in the clinical practice, only palliative measures are used to treat the IM, which represent the main clinical limitation in management this condition. In this scenario, the repurposing of compounds that are already in clinical use highlight as a rapid and effective strategy against IM caused by chemotherapy. The use of thalidomide has already been demonstrated as a good therapeutic option in preclinical models of irinotecan-induced IM, due its ability to modulate proinflammatory response and to reduce the levels of enterotoxic metabolite of this antitumor agent (i.e., SN-38). In this sense, thalidomide appears as a promising compound for repositioning the therapy of IM, since it exhibits high clinical efficacy and does not affect the activity of ongoing antitumor treatment.

Suggested Citation

  • Rafaela Miranda Pessoa & William Gustavo Lima & Kátia Duarte Vital & Valbert Nascimento Cardoso & Simone Odília Antunes Fernandes, 2018. "Repurposing the Thalidomide to the Treatment of Irinotecan-Induced Intestinal Mucositis: An Old Drug to a New Use," Global Journal of Pharmacy & Pharmaceutical Sciences, Juniper Publishers Inc., vol. 6(2), pages 33-35, October.
    • Handle: RePEc:adp:jgjpps:v:6:y:2018:i:2:p:33-35
    DOI: 10.19080/GJPPS.2018.06.555682
    as

    Download full text from publisher

    File URL: https://juniperpublishers.com/gjpps/pdf/GJPPS.MS.ID.555682.pdf
    Download Restriction: no
    File URL: https://juniperpublishers.com/gjpps/GJPPS.MS.ID.555682.php
    Download Restriction: no
    File URL: https://libkey.io/10.19080/GJPPS.2018.06.555682?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:adp:jgjpps:v:6:y:2018:i:2:p:33-35. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Robert Thomas (email available below). General contact details of provider: .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.